key: cord-1019757-3vr2sv1d
authors: Cohen-Dvashi, Hadas; Weinstein, Jonathan; Katz, Michael; Eilon, Maayan; Mor, Yuval; Shimon, Amir; Strobelt, Romano; Shemesh, Maya; Fleishman, Sarel J; Diskin, Ron
title: Coronacept – a potent immunoadhesin against SARS-CoV-2
date: 2020-08-12
journal: bioRxiv
DOI: 10.1101/2020.08.12.247940
sha: ef8cd37479a05f9485ec2fd2c1bacd4d5ffc5f3c
doc_id: 1019757
cord_uid: 3vr2sv1d

Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Computational analysis of mammalian ACE2 orthologues suggests various residues at the interface with the viral receptor binding domain that could facilitate tighter interaction compared to the human-ACE2. Introducing several mutations to the human-ACE2 resulted with significantly augmented affinity to the viral spike complex. This modified human-ACE2 fused to an Fc portion of an antibody makes a potent immunoadhesin that effectively targets SARS-CoV-2.

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing devastating pandemic leading to a substantial global death toll and an unprecedented economic loss. There is an urgent need for anti-viral countermeasures that will help to save lives as well as shorten the recovery and hospitalization time of sick people. Immunotherapy has the potential to neutralize viruses directly as well as to recruit immune effector functions to clear infected cells, and it makes a promising approach that was already shown to be beneficial in combating other viral diseases. A monoclonal antibody (mAb) against the respiratory syncytial virus is effective and was approved for treating infected children 1, 2 . A breakthrough in the field of HIV was the isolation of broadly-neutralizing mAbs 3, 4 and the affirmation of their use in treating 5,6 and protecting 7, 8 individuals from HIV-1. In addition, antibodies against Lassa 9 , Junin 10 , Ebola 11 , and even SARS 12 viruses have been proven effective in animal models.

Preliminary reports indicate that also in the case of COVID-19, sera from convalescent patients help to fight the disease 13, 14 . Hence, targeted immunotherapy may become a powerful anti-viral tool for fighting it would be important to diversify our immunotherapeutic toolkit to maximize the chances for success.

Diversification may be achieved using immunoadhesins, which are antibody-like molecules that consist of a binding domain fused to an Fc portion on an antibody 18 . The viral cellular receptor could serve as a binding domain for constructing such immunoadhesins. Due to natural adaptation, however, zoonotic viruses may bind to their animal-derived ortholog cellular receptors at higher affinities than the human cell-surface receptors 19 . Thus, immunoadhesins that are constructed with the host-ortholog receptors can provide superior anti-viral therapeutics. We recently demonstrated this approach by constructing Arenacept, which is a powerful immunoadhesin that targets viruses from the Arenaviridae family of viruses 20 .

SARS-CoV-2 is a zoonotic virus that utilizes angiotensin-converting enzyme 2 (ACE2) as a cellular receptor [21] [22] [23] . The genome of SARS-CoV-2 is similar to bat-derived SARS-like coronaviruses 24 , but the exact origin of the virus is unknown and other animal species may have served as intermediate reservoirs before SARS-CoV-2 crossed over to the human population 25 . It was shown that ACE2 orthologs from various animals can serve as entry receptors for SARS-CoV-2 26 . Furthermore, it was demonstrated that the human-ACE2 is a suboptimal receptor for SARS-CoV-2 27 . We therefore reasoned that the human-ACE2 could be modified to make it a superior binder of SARS-CoV-2.

Such an engineered ACE2 may be better suited for therapeutic applications than the human ACE2.

The binding of SARS-CoV-2 to its ACE2 receptors is mediated by the receptor-binding domain (RBD), which is part of its spike complex 23, [28] [29] [30] . ACE2 has a long helical segment at its N' terminus, which forms most of the RBD-recognition site on ACE2 (Fig. 1a) . A multiple sequence alignment of over 200 ACE2 sequences derived from mammals indicates that many of the ACE2 positions that comprise the SARS-CoV-2 recognition site are not conserved (Fig. 1b) . This notion indicates an enormous putative sequence space that ACE2 can adopt.

To identify advantageous alterations of ACE2 that may enhance the binding to SARS-CoV-2, we selected 70 orthologous ACE2 genes with sequence identity to the human-ACE2 greater than 80%.

We used Rosetta atomistic modelling calculations to assess the stability, binding energy (ΔΔGbind), interface packing and shape complementarity for the RBD (starting from PDB entry 6VW1) (Fig. 1c ) 30 . We visually inspected the top-20 models according to ΔΔGbind and identified mutations that the calculations indicated would improve contacts with the SARS-CoV-2 RBD relative to the human ACE2. Due to the high sequence diversity in ACE2, many design options were available. We rejected mutations to Trp, due to their tendency to form undesired promiscuous interactions and furthermore consulted a recent deep mutational sequencing dataset on ACE2 mutations and their impact on binding to the RBD 27 eliminating mutations that were depleted in this dataset.

Three of the mutations that we decided to incorporate are located at the first N'-terminal helix of human-ACE2. These three mutations include a T27L mutation that improves packing with hydrophobic residues of SARS-CoV-2 RBD (Fig. 2a) , a D30E mutation that forms a new salt-bridge with Lys417 of SARS-CoV-2 RBD (Fig. 2b) , and a Q42R mutation that may form a salt-bridge with Asp38 of ACE2 and stabilize it in a configuration that favors the formation of a hydrogen bond with Tyr449 of SARS-CoV-2 RBD (Fig. 2c) . Alternatively, the new arginine may assume a different rotamer that makes favorable electrostatic interactions with the main-chain carboxylic oxygen of Gly447 from the SARS-CoV-2 RBD (Fig. 2c ). Besides these three mutations at the N-terminal helix of ACE2 that we selected, we identified two additional sites in the surrounding regions of ACE2. In the first site, we identified a putative change of Glu75 and Leu79 to arginine and tyrosine, respectively, that may interact favorably with Phe486 of SARS-CoV-2 RBD (Fig. 2d ). In the second site outside the first helix of ACE2, N330F may improve packing against the aliphatic portion of Thr500 from SARS-CoV-2 RBD (Fig. 2e) . We used Rosetta to model the combination of these six mutations and its impact on the binding to SARS-CoV-2 RBD. Our design showed a remarkable improvement in ΔΔG of binding as well as in the buried surface area (Fig. 1c) .

We decided to incorporate additional modification at other sites on top of modifying ACE2 residues that directly interact with SARS-CoV-2 RBD. Human-ACE2 has a putative glycosylation site at Asn90 that was shown to bear a glycan according to the SARS-CoV-2 RBD/human-ACE2 cryo-EM structure 21 . This N-linked glycan projects toward the SARS-CoV-2 RBD, and presumably imposes steric constraints for the binding of SARS-CoV-2 RBD. The aforementioned deep mutational scanning dataset 27 is highly enriched with mutations in this N-linked glycosylation site, further supporting this notion. To eliminate this glycosylation site, we mutated Thr92 from the N-X-T glycosylation motif to an arginine that can make polar interactions with nearby glutamine (Fig. 2f) .

Besides serving as a cellular receptor for SARS-CoV-2, ACE2 is an enzyme that has a critical biological function in regulating blood pressure by hydrolyzing angiotensin II 31 . Since the enzymatic activity of the engineered ACE2 may complicate its therapeutic use, we also mutated its key catalytic position Glu375 to leucine.

To test our design, we produced two chimeric proteins that included amino acids 19-615 of the human-ACE2 ectodomain (omitting the original signal peptide) fused to an Fc portion of human IgG1, with or without the eight above-mentioned mutations (i.e., T27L, D30E, Q42R, E75R, L79Y, N330F, T92R, & E375L). Both the WT construct (ACE2-Fc) and our designed ACE2 construct (ACE2 mod -Fc) readily expressed as secreted proteins using HEK293F cells in suspension and were easily purified to near homogeneity using protein-A affinity chromatography (Fig. 3a) . Testing the enzymatic activity of both ACE2-Fc and ACE2 mod -Fc verified that the latter is indeed catalytic dead ( Supplementary Fig.   1 ). We then immobilized the two immunoadhesins on a surface plasmon resonance sensor chip and used purified SARS-CoV-2 RBD as an analyte to determine their binding affinities, which is a configuration that does not allow avidity. A simple 1:1 binding model gave a good fit for the binding data of ACE2 mod -Fc to SARS-CoV-2 RBD, but the binding of ACE2-Fc to SARS-CoV-2 RBD could not be fitted using this model, and we, therefore, used a more complex heterogeneous-ligand model that assumes some heterogeneity of the ACE2-Fc (Fig. 3b) . Such heterogeneity could presumably originate from partial glycosylation at Asn90 of ACE2. Remarkably, the binding affinity of ACE2 mod -Fc to SARS-CoV-2 RBD is more than two orders of magnitude stronger compared with the binding affinity of ACE2-Fc (Fig. 3b) . While the association rate (ka) of ACE2 mod -Fc to SARS-CoV-2 RBD is somewhat faster compared to ACE2-Fc, the improvement mainly stems from a dramatic two-orders of magnitude slower dissociation rate (kd).

To test if the enhanced affinity of ACE2 mod -Fc could translate to improved biological functions, we conducted a pseudovirus neutralization assay. The neutralization profile of ACE2 mod -Fc is apparently better compared to the profile of ACE2-Fc (Fig. 4a ). There is more than a 10-fold improvement in both IC50 and IC80 values, comparing the two reagents. Anti SARS-CoV-2 immunoadhesin that binds to cell-surface displayed spike complexes might recruit beneficial immune factions via its Fc portion.

We used flow cytometry to monitor the ability of ACE2-Fc and of ACE2 mod -Fc to stain HEK293 cells that were transiently transfected express the SARS-CoV-2 spike complex (Fig. 4b) . ACE2 mod -Fc has an apparent higher capacity to recognize the spike complex compared to ACE2-Fc. Altogether, we created a superior ACE2-based immunoadhesin that displays an improved capacity to target SARS-CoV-2.

Immunotherapy makes a promising avenue to combat the COVID-19 pandemic. ACE2-based immunoadhesins were already described in the literature 26, 32 . However, reagents based on human-ACE2 have limited potency, and they can only compete in a stoichiometric fashion with the abundant natural ACE2 receptor on cells. An improved ACE2 binder, like the one we present here, is a more efficient competitor for binding to the SARS-CoV-2 RBD. Neutralization of the virus by blocking the receptor binding site is a mechanism that is shared by some anti-SARS-CoV-2 RBD mAbs that were recently isolated [15] [16] [17] . Nevertheless, ACE2 mod -Fc is likely to interact solely with the residues that make the ACE2 binding site, whereas the epitopes of anti-RBD mAbs are likely to only partially overlap with the ACE2-binidng surface, which may contribute for the emergence of escape mutations.

Altogether we present a promising immunoadhesin that we now term Coronacept, which is a candidate immunotherapeutic agent for COVID-19.

Atomistic modeling-Orthologous sequences of ACE2 were collected by using a protein BLAST 33 search of the human-ACE2 sequence at GenBank and filtering the results to mammalian origin, and to sequences with greater than 80% identity to human-ACE2. Sequences were aligned using MUSCLE 34 . Each sequence was threaded on the human-ACE2/Spike structure (PDB entry: 6VW1) and relaxed using sidechain packing and backbone, sidechain and rigid-body minimization subject to harmonic constraints on the Cα coordinates observed in the experimental structure. The ref2015 energy function was used in all calculations (xml and command line are provided in the Supplementary information). 100 models were generated for each sequence and the best scoring one was used for comparisons and analyses.

(amino-acids 19-615) and modified ACE2 genes were chemically synthesized (Genscript), and were subcloned upstream of a human Fc region (derived from IgG1) as previously described 35 . Plasmid 

The Weizmann Institute has filed for a patent for Coronacept. The abundance of the amino acid types in each position is represented by the height of their singleletter code. The residues that interact with the RBD of SARS-CoV-2 are indicated by red arrows. c.

Interface properties of the various RBS/ACE2-ortholog models. Each dot represents a single model.

From left to right, five panels show the calculated total Rosetta energy (using Rosetta energy units), the binding energy (ΔΔG for binding), the buried surface area, the packing statistics, and the shape complementarity of the interface. All the panels are arranged such that the values at the top represent better results. The RBD/human-ACE is indicated with a green dot. The modified ACE2 is indicated with a red dot. The concentration-depended ability of ACE2-Fc (grey) and ACE2 mod -Fc (red) to bind to surfacedisplayed SARS-CoV-2 spike complexes is analysed using flow cytometry. Normalized overall fluorescence signals for the gate-selected cells are shown. This experiment was repeated three times, and a representative graph is shown. 

New options in the treatment of respiratory syncytial virus disease

Structural basis of respiratory syncytial virus neutralization by motavizumab

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Monoclonal antibody therapy for Junin virus infection

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. bioRxiv

Designing CD4 immunoadhesins for AIDS therapy

Structural basis for receptor selectivity by the Whitewater Arroyo mammarenavirus

Rational design of universal immunotherapy for TfR1-tropic arenaviruses

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2

Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1. bioRxiv

The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2. bioRxiv

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structural basis of receptor recognition by SARS-CoV-2

A. ACE2 of the heart: From angiotensin I to angiotensin

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Basic local alignment search tool

MUSCLE: multiple sequence alignment with high accuracy and high throughput

Molecular Mechanism for LAMP1 Recognition by Lassa Virus

A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv

We are grateful to Julia Adler and Yosef Shaul for providing plasmids for the lentivirus system. Ron